ES2302728T3 - Uso de sustancias con actividad oxitocina contra trastornos climatericos. - Google Patents

Uso de sustancias con actividad oxitocina contra trastornos climatericos. Download PDF

Info

Publication number
ES2302728T3
ES2302728T3 ES01922220T ES01922220T ES2302728T3 ES 2302728 T3 ES2302728 T3 ES 2302728T3 ES 01922220 T ES01922220 T ES 01922220T ES 01922220 T ES01922220 T ES 01922220T ES 2302728 T3 ES2302728 T3 ES 2302728T3
Authority
ES
Spain
Prior art keywords
baselineskip
sec
oxytocin
group
nothing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES01922220T
Other languages
English (en)
Spanish (es)
Inventor
Kerstin Uvnas-Moberg
Thomas Lundeberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
EntreTech Medical AB
Original Assignee
EntreTech Medical AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by EntreTech Medical AB filed Critical EntreTech Medical AB
Application granted granted Critical
Publication of ES2302728T3 publication Critical patent/ES2302728T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
ES01922220T 2000-04-18 2001-04-18 Uso de sustancias con actividad oxitocina contra trastornos climatericos. Expired - Lifetime ES2302728T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0001440 2000-04-18
SE0001440A SE0001440D0 (sv) 2000-04-18 2000-04-18 A drug against climacteric disorders

Publications (1)

Publication Number Publication Date
ES2302728T3 true ES2302728T3 (es) 2008-08-01

Family

ID=20279369

Family Applications (1)

Application Number Title Priority Date Filing Date
ES01922220T Expired - Lifetime ES2302728T3 (es) 2000-04-18 2001-04-18 Uso de sustancias con actividad oxitocina contra trastornos climatericos.

Country Status (8)

Country Link
US (2) US20040029787A1 (fr)
EP (1) EP1406649B9 (fr)
AT (1) ATE387213T1 (fr)
AU (1) AU2001248994A1 (fr)
DE (1) DE60133050T2 (fr)
ES (1) ES2302728T3 (fr)
SE (1) SE0001440D0 (fr)
WO (1) WO2001078758A1 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0100684D0 (sv) * 2001-02-28 2001-02-28 Kerstin Uvnaes Moberg New subject-matter
JO2937B1 (en) 2004-08-11 2016-03-15 فيرينغ.بي.في Tight muscles of the peptide vascular tensioner receptor
RU2415149C2 (ru) 2006-02-10 2011-03-27 Ферринг Б.В. Пептидные соединения
EP2175874A2 (fr) 2007-08-14 2010-04-21 Ferring B.V. Utilisation d'agonistes peptidiques du récepteur de la vasopressine
KR20100061677A (ko) * 2007-09-11 2010-06-08 몬도바이오테크 래보래토리즈 아게 치료제로서의 ｔｙｒ-ｗ-ｍｉｆ-1 및 유로코르틴 2의 용도
CA2698768A1 (fr) * 2007-09-11 2009-04-02 Dorian Bevec Utilisation d'un peptide en tant qu'agent therapeutique
US20100323950A1 (en) * 2007-09-11 2010-12-23 Dorian Bevec Use of beta-melanotropin as a therapeutic agent, eg for the treatment of aids or alzheimer
WO2009033820A2 (fr) * 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Utilisation d'un peptide en tant qu'agent thérapeutique
CA2698691A1 (fr) * 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Utilisation d'un peptide en tant qu'agent therapeutique
SE536091C2 (sv) 2011-04-14 2013-04-30 Pep Tonic Medical Ab Farmaceutisk komposition innehållande oxytocin eller fragment eller varianter därav och åtminstone en icke-jonisk cellulosaeter
EP2908840A1 (fr) * 2012-10-12 2015-08-26 Peptonic Medical AB Nouvelle utilisation d'une composition comprenant de l'oxytocine
SE1750680A1 (en) 2017-05-30 2018-12-01 Peptonic Medical Ab Composition for treating or preventing climacteric disorders

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4889844A (en) * 1985-10-22 1989-12-26 Silvetti Sr Anthony N Fructose containing wound healing preparation
US5457128A (en) * 1992-03-28 1995-10-10 Dott Limited Company Topical preparation for healing wounds of the skin
CO4560488A1 (es) * 1995-10-03 1998-02-10 Nor Ind Inc Composiciones limpiadoras para pozos de lineas, carcasas, formaciones y equipo de petroleo y gas .
US5753266A (en) * 1996-12-03 1998-05-19 Youssefyeh; Parvin Safflower seed powder compositions for the treatment of rheumatoid based arthritic diseases
SE9701162D0 (sv) * 1997-03-27 1997-03-27 Karolinska Innovations Ab New use II
SE9803272D0 (sv) * 1998-09-25 1998-09-25 Kerstin Uvnaes Moberg A drug for cell regeneration
US6333313B1 (en) * 1998-10-29 2001-12-25 Board Of Regents, The University Of Texas System Clinical use of oxytocin alone or in combination to treat bone disorders
SE0100684D0 (sv) 2001-02-28 2001-02-28 Kerstin Uvnaes Moberg New subject-matter

Also Published As

Publication number Publication date
DE60133050T2 (de) 2009-02-26
US20060148685A1 (en) 2006-07-06
WO2001078758A1 (fr) 2001-10-25
AU2001248994A1 (en) 2001-10-30
US7727959B2 (en) 2010-06-01
EP1406649B9 (fr) 2008-10-15
EP1406649B1 (fr) 2008-02-27
DE60133050D1 (de) 2008-04-10
EP1406649A1 (fr) 2004-04-14
US20040029787A1 (en) 2004-02-12
SE0001440D0 (sv) 2000-04-18
ATE387213T1 (de) 2008-03-15

Similar Documents

Publication Publication Date Title
US7727959B2 (en) Use of substances with oxytocin activity against climacteric disorders
Neumann et al. Oxytocin released within the supraoptic nucleus of the rat brain by positive feedback action is involved in parturition‐related events
US20210308223A1 (en) Peptide yy pharmaceutical formulations, compositions, and methods
ES2318756T3 (es) Formulaciones mucoadhesivas que contienen xiloglucano utiles en dispositivos medicos y en presentaciones farmaceuticas.
ES2281169T3 (es) Uso de un extracto enriquecido en biocanina para el tratamiento de trastornos asociados a estrogenos.
ES2728117T3 (es) Complemento alimenticio biológicamente activo para la prevención de la osteoporosis
ES2659316T3 (es) Procedimientos para administrar formas de dosificación sólidas de etinilestradiol y profármacos del mismo con biodisponibilidad mejorada
KR930003332B1 (ko) 항이뇨제 ddavp의 경구 투여용 제제의 제조방법
RU2409357C2 (ru) Композиции для пероральной доставки метформина через слизистые оболочки
EP1115416B1 (fr) Utilisation de substances ayant une activite oxytocique pour la regeneration cellulaire
EP1370277B1 (fr) Utilisation de l'ocytocine dans la preparation d'une composition pharmaceutique contre le cancer in situ et la cervicite
RU2233666C1 (ru) Таблетки "апилар" на основе трутневого расплода, обладающие анаболическим, актопротекторным действием
CA3037040A1 (fr) Compositions de finasteride et de sildenafil et applications
US20060234919A1 (en) Use
RU2220712C1 (ru) Средство и набор для нормализации функциональных нарушений, возникающих в предклимактерический и климактерический период
US9925216B2 (en) Mixture of un-refined salt and sugar in the manufacture of a medicament employed for treating lax vagina syndrome or colpoxerosis disease in an mammal
JPH04235923A (ja) 経鼻投与用製剤
ES2628709T3 (es) Composición para controlar y mejorar la gametogénesis femenina y masculina.
JPH01501708A (ja) アミノ酸の経鼻投与
Mussio Fournier et al. Recientes progresos de la endocrinología
Tracy A Bit of Hormonology, with Practical Applications